Abstract
Background
Several cardiac biomarkers have been shown to have predictive values for the development of cardiovascular disease and clinical outcome after events, and are now broadly used by clinicians. Little is known about the utility of these biomarker values on admission in ST‐elevation myocardial infarction (STEMI) cases of primary drug‐eluting stent (DES) implantation and intense medical therapy.
Hypothesis
Because little is known about the utility of these biomarkers on admission in ST‐elevation myocardial infarction (STEMI) in cases primary drug‐eluting stent (DES) implantation and intense medical therapy, we evaluated clinical outcomes.
Methods
We enrolled 207 consecutive STEMI patients treated with primary stenting (mean age, 57.3 ± 12.0 y). We evaluated the association between B‐type natriuretic peptide (BNP), cardiac troponin I (cTnI), high‐sensitivity C‐reactive protein (hs‐CRP) on admission, and death, reinfarction, and new or worsening congestive heart failure (CHF) through 1 y.
Results
In backward‐elimination models including all biomarkers, only the cTnI level was retained as a predictor of 1‐y CHF (odds ratio [OR]: 1.017, 95% confidence interval [CI]: 1.001–1.034, p = 0.039). There were no predictors in terms of 1‐y death, reinfarction, and composite endpoint. When we applied a simple score system, in which patients were categorized on the basis of the number of elevated biomarkers, the 1‐y risks of death (p = 0.600), reinfarction (p = 0.185), and composite endpoint (p = 0.620) did not increase in proportion to the number of elevated biomarkers on admission. One‐y CHF only tended to increase according to the number of elevated biomarkers (p = 0.067).
Conclusions
The use of cardiac biomarkers on admission, in each or in combination, had only a minimal impact for the prediction of long‐term cardiovascular events after primary stenting in STEMI patients. Copyright © 2008 Wiley Periodicals, Inc.
Keywords: biomarker, thrombolysis in myocardial infarction risk score, ST‐elevation myocardial infarction, drug‐eluting stent
Full Text
The Full Text of this article is available as a PDF (121.8 KB).
References
- 1. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631–2639. [DOI] [PubMed] [Google Scholar]
- 2. de Lemos JA, McGuire DK, Drazner MH: B‐type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316–322. [DOI] [PubMed] [Google Scholar]
- 3. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, et al.: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long‐term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N‐terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963–1969. [DOI] [PubMed] [Google Scholar]
- 4. Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, et al.: Early prognostic usefulness of C‐reactive protein added to the thrombolysis in myocardial infarction risk score in acute coronary syndromes. Am J Cardiol 2005; 96: 533–537. [DOI] [PubMed] [Google Scholar]
- 5. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, et al.: Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82–91. [DOI] [PubMed] [Google Scholar]
- 6. Hoffmann R, Suliman H, Haager P, Christott P, Lepper W, et al.: Association of C‐reactive protein and myocardial perfusion in patients with ST‐elevation acute myocardial infarction. Atherosclerosis 2006; 186: 177–183. [DOI] [PubMed] [Google Scholar]
- 7. Mega JL, Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, et al.: B‐type natriuretic peptide at presentation and prognosis in patients with ST‐segment elevation myocardial infarction; an ENTIRE‐TIMI‐23substudy. J Am Coll Cardiol 2004; 44: 335–339. [DOI] [PubMed] [Google Scholar]
- 8. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, et al.: Multimarker approach to risk stratification in non‐ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C‐reactive protein and B‐type natriuretic peptide. Circulation 2002; 105: 1760–1763. [DOI] [PubMed] [Google Scholar]
- 9. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, et al.; A to Z Investigators: Prognostic value of serial B‐type natriuretic peptide testing during follow‐up of patients with unstable coronary artery disease. JAMA 2005; 294: 2866–2871. [DOI] [PubMed] [Google Scholar]
- 10. Niccoli G, Lanza GA, Spaziani C, Altamura L, Romagnoli E, et al.: Baseline systemic inflammatory status and no‐reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 2007; 117: 306–311. [DOI] [PubMed] [Google Scholar]
- 11. Wilson RF, Laxson DD, Lesser JR, White CW: Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesion. Lancet 1989; 1: 807–811. [DOI] [PubMed] [Google Scholar]
- 12. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, et al.; Academic Research Consortium: Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344–2351. [DOI] [PubMed] [Google Scholar]
- 13. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, et al.: N‐terminal pro‐brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV substudy. Circulation 2003; 108: 275–281. [DOI] [PubMed] [Google Scholar]
- 14. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, et al.: Evaluation of B‐type natriuretic peptide for risk assessment in unstable angina/non‐ST‐elevation myocardial infarction: B‐type natriuretic peptide and prognosis in TACTICS‐TIMI 18. J Am Coll Cardiol 2003; 41: 1264–1272. [DOI] [PubMed] [Google Scholar]
- 15. Talwar S, Squire IB, Downie PF, Mccullough AM, Campton MC, et al.: Profile of plasma N‐terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21: 1514–1521. [DOI] [PubMed] [Google Scholar]
- 16. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, et al.: Plasma N‐terminal pre‐brain natriretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921–1929. [DOI] [PubMed] [Google Scholar]
- 17. Grabowski M, Filipiak KJ, Karpinski G, Wretowski D, Rdzanek A, et al.: Serum B‐type natriuretic peptide levels on admission predict not only short‐term death but also angiographic success of procedure in patients with acute ST‐elevation myocardial infarction treated with primary angioplasty. Am Heart J 2004; 148: 655–662. [DOI] [PubMed] [Google Scholar]
- 18. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, et al.; TYPHOON Investigators: Sirolimus‐eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093–1104. [DOI] [PubMed] [Google Scholar]
- 19. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, et al.: Paclitaxel‐eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105–1113. [DOI] [PubMed] [Google Scholar]
- 20. Robinson CR, Martin JL, Zhang L, Canham RM, Abdullah SM, et al.: Infarct‐related coronary artery patency and medication use prior to ST‐segment elevation myocardial infarction. Am J Cardiol 2006; 97: 7–9. [DOI] [PubMed] [Google Scholar]
- 21. Ohman EM, Armstrong PW, White HD, Granger CB, Wilcox RG, et al.: Risk stratification with a point‐of‐care cardiac troponin T test in acute myocardial infarction. The GUSTO III Investigators Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 84: 1281–1286. [DOI] [PubMed] [Google Scholar]